Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 113 for “"Enzyme replacement therapy"”.

  1. Improving enzyme replacement therapy for lysosomal storage diseases

    … whereby the deficiency of a single lysosomal enzyme leads to accumulation of metabolites in the lysosome cells. This in turn results in cellular dysfunction and clinical abnormalities such as enlarged organs, connective-tissue, ocular pathology and central nervous system dysfunction. To date, …

    fu-berlin Repository record for Improving enzyme replacement therapy for lysosomal storage diseases (opens in a new tab)

  2. Enzyme-replacement therapy in lysosomal storage diseases / Julie Bielicki.

    … dog to demonstrate the effectiveness of enzyme-replacement therapy (ERT) in lysosomal storage diseases (LSD). Pathology in these animal models closely parallels that observed in the human condition. In terms of therapeutic strategies, the results described in this thesis indicate that the …

    adelaide Repository record for Enzyme-replacement therapy in lysosomal storage diseases / Julie Bielicki. (opens in a new tab)

  3. Potential Modifications to Enzyme Replacement Therapy in Anderson-Fabry Disease

    … in the GLA gene that encodes the lysosomal enzyme α-galactosidase A (αGal) result in the sphingolipidoses named Fabry disease. This enzymatic defect is inherited as an X-linked recessive disorder and is associated with a progressive deposition of glycosphingolipids, including …

    cuny-grad Repository record for Potential Modifications to Enzyme Replacement Therapy in Anderson-Fabry Disease (opens in a new tab)

  4. Development of Enzyme Replacement Therapy in Mammalian Models of Barth Syndrome

    … A curative treatment is still an unmet need. TAZ enzyme replacement therapy (ERT) could significantly benefit patients suffering from this disorder. The studies presented here focus on the design and development of a recombinant TAZ protein containing a cell penetrating peptide for the treatment …

    washington Repository record for Development of Enzyme Replacement Therapy in Mammalian Models of Barth Syndrome (opens in a new tab)

  5. Enzyme replacement therapy in a feline model of mucopolysaccharidosis type VI / Allison Catherine Crawley.

    Evaluates the efficacy of enzyme replacement therapy (ERT) with artifically produced recombinant human 4S (rh4S) in feline mucopolysaccharidosis Type VI (MPS VI) and tests the hypothesis that this form of therapy would reverse or alter the disease course, particularly the bone dysplasia and …

    adelaide Repository record for Enzyme replacement therapy in a feline model of mucopolysaccharidosis type VI / Allison Catherine Crawley. (opens in a new tab)

  6. Enzyme replacement therapy in a murine model of mucopolysaccharidosis type IIIA / by Briony Lee Gliddon.

    … IIIA is caused by a deficiency of the lysosomal enzyme sulphamidase which is needed together with other exohydrolases and a N-acetyltransferase to break down the glycosaminoglycan heparan sulphate to sulphate and monosaccharides. Patients are characterised by severe central nervous systems …

    adelaide Repository record for Enzyme replacement therapy in a murine model of mucopolysaccharidosis type IIIA / by Briony Lee Gliddon. (opens in a new tab)

  7. Impact of kidney biopsy on deciding when to initiate enzyme replacement therapy in children with Fabry disease

    zurich Restricted access

  8. Study of fat digestion in foods as an innovative approach to adjust pancreatic enzyme replacement therapy in Cystic Fibrosis

    La terapia de sustitución enzimática (PERT) es el tratamiento para paliar la insuficiencia pancreática en fibrosis quística. Consiste en la administración exógena de suplementos enzimáticos en cada comida. Sin embargo, hasta la fecha no hay un método científicamente válido para ajustar la dosis, lo …

    upv Repository record for Study of fat digestion in foods as an innovative approach to adjust pancreatic enzyme replacement therapy in Cystic Fibrosis (opens in a new tab)

  9. Using an engineered human hexosaminidase as an enzyme replacement therapy to treat a mouse model of Tay-Sachs Disease

    … Hexosaminidase A is a member of a family of enzymes that are involved in the degradation of glycoconjucates including glycolipids and glycosphingolipids. These molecules are components of cell membranes and have important roles in cellular signaling processes, cell-surface recognition, cell …

    manitoba Repository record for Using an engineered human hexosaminidase as an enzyme replacement therapy to treat a mouse model of Tay-Sachs Disease (opens in a new tab)

  10. Elucidating the structure and improving the cellular uptake of HexM, a candidate for enzyme replacement therapy of GM2 gangliosidosis

    … include the inability to produce therapeutic enzyme in sufficient quantities and inadequate enzyme phosphorylation, which is necessary for uptake into lysosomes of affected cells by the manose-6-phophate pathway). Here I demonstrate that HexM can be produced in gram-scale quantities, making it …

    manitoba Repository record for Elucidating the structure and improving the cellular uptake of HexM, a candidate for enzyme replacement therapy of GM2 gangliosidosis (opens in a new tab)

  11. Pupillary Light Reflex Deficits in a Canine Model of Neuronal Ceroid Lipofuscinosis and the Effects of Enzyme Replacement Therapy

    … peptidase-1 (TPP1), a soluble, lysosomal enzyme that aids degradation of peptides in cells throughout the body. A Dachshund model of CLN2 was developed and is currently being maintained at the University of Missouri. Dogs affected by CLN2 lack functional TPP1 and present with xvi …

    missouri Repository record for Pupillary Light Reflex Deficits in a Canine Model of Neuronal Ceroid Lipofuscinosis and the Effects of Enzyme Replacement Therapy (opens in a new tab)

  12. Enzyme replacement therapy treatment from birth increases therapeutic efficacy and generates tolerance to enzyme in canine mucopolysaccharidosis type I

    … I dogs with intravenous recombinant enzyme replacement therapy at the conventional 0.58 mg/kg or a higher 1.57 mg/kg weekly dose. Higher dosage led to complete normalization of lysosomal storage in liver, spleen, lung, kidney, synovium and myocardium, as well as normalization of …

    iastate Repository record for Enzyme replacement therapy treatment from birth increases therapeutic efficacy and generates tolerance to enzyme in canine mucopolysaccharidosis type I (opens in a new tab)

  13. Evaluating an Exercise Training Approach to Enhance Muscle Function and Mitigate Pathology in Pompe Disease Patients on Enzyme Replacement Therapy

    … in the GAA gene encoding acid α-glucosidase, the enzyme responsible for lysosomal glycogen degradation. Reduced enzyme activity leads to glycogen accumulation in skeletal muscle, impaired autophagic flux, enlarged and dysmorphic mitochondria, and increased production of reactive oxygen species …

    mcmaster Repository record for Evaluating an Exercise Training Approach to Enhance Muscle Function and Mitigate Pathology in Pompe Disease Patients on Enzyme Replacement Therapy (opens in a new tab)

  14. Apžvalga: Kasos fermentų pakaitinės terapijos efektyvumas sergant virškinamojo trakto funkciniais susirgimais: ar tikslinga skirti? /

    … is to evaluate the effectiveness of pancreatic enzyme replacement therapy in treating functional gastrointestinal disorders. Functional gastrointestinal disorders encompass a spectrum of chronic gastrointestinal conditions that lack an obvious structural or biochemical cause. Symptoms include …

    vilnius Repository record for Apžvalga: Kasos fermentų pakaitinės terapijos efektyvumas sergant virškinamojo trakto funkciniais susirgimais: ar tikslinga skirti? / (opens in a new tab)

  15. Hypophosphastasia (HPP): pathogenesis and current treatment options

    … management of HPP focused solely on supportive therapy in an attempt to minimize disease-related symptoms (1,2). However, in 2015, the Food and Drug Administration (FDA) approved Strensiq® (asfotase alfa), an enzyme replacement therapy approved for the treatment of patients with …

    bu Repository record for Hypophosphastasia (HPP): pathogenesis and current treatment options (opens in a new tab)

  16. The molecular genetics of mucopolysaccharidosis type I / by Hamish Steele Scott.

    … disease prognosis, and make possible new therapy protocols such as enzyme replacement therapy and gene replacement therapy.

    adelaide Repository record for The molecular genetics of mucopolysaccharidosis type I / by Hamish Steele Scott. (opens in a new tab)

Page 1 of 6